Eli Lilly and (LLY) Stock News

Large caps closed near record territory while small caps lagged. Deal flow included a $6.3B RTX missile contract, Lilly FDA approval for Jaypirca, Couche-Tard retail asset acquisition, SAP's TechWolf acquisition, and a CN Rail grain record.

Lilly Phase 3b data show broader biomarker changes with Taltz and Zepbound in psoriasis and obesity.

FDA approved Jaypirca for previously untreated CLL/SLL without 17p deletion. In the BRUIN CLL-313 trial, pirtobrutinib showed a 94% ORR and significantly improved PFS versus bendamustine plus rituximab (HR=0.20; median PFS not reached vs 33.5 months). Jaypirca is the first non-covalent BTK inhibitor approved in the first-line setting.

The FDA approved Eli Lilly's Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin injection for adults with type 2 diabetes. Lilly says the treatment could reduce injections by over 300 per year versus daily basal insulin. U.S. availability expected in coming months.

Eli Lilly said its Onswik is designed to reduce the number of injections by more than 300 per year compared to once-daily basal insulin. The statement did not provide further details.

Eli Lilly breaks ground on $6.5B Houston plant for oral GLP-1 drug Foundayo.

Eli Lilly's Mounjaro receives FDA approval to reduce heart disease risks.